Details

Autor(en) / Beteiligte

• Turaga, K.
• Levine, E.
• Barone, R.
• Sticca, R.
• Petrelli, N.
• Lambert, L.
• Nash, G.
• Morse, M.
• Adbel-Misih, R.
• Alexander, H. R.
• Attiyeh, F.
• Bartlett, D.
• Bastidas, A.
• Blazer, T.
• Chu, Q.
• Chung, K.
• Dominguez-Parra, L.
• Espat, N. J.
• Foster, J.
• Fournier, K.
• Garcia, R.
• Goodman, M.
• Hanna, N.
• Harrison, L.
• Hoefer, R.
• Holtzman, M.
• Kane, J.
• Labow, D.
• Li, B.
• Lowy, A.
• Mansfield, P.
• Ong, E.
• Pameijer, C.
• Pingpank, J.
• Quinones, M.
• Royal, R.
• Salti, G.
• Sardi, A.
• Shen, P.
• Skitzki, J.
• Spellman, J.
• Stewart, J.
• Esquivel, J.

Titel

Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States

Ist Teil von

• Annals of surgical oncology, 2014-05, Vol.21 (5), p.1501-1505

Ort / Verlag

Boston: Springer US

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Background The American Society of Peritoneal Surface Malignancies (ASPSM) is a consortium of cancer centers performing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). This is a position paper from the ASPSM on the standardization of the delivery of HIPEC. Methods A survey was conducted of all cancer centers performing HIPEC in the United States. We attempted to obtain consensus by the modified method of Delphi on seven key HIPEC parameters: (1) method, (2) inflow temperature, (3) perfusate volume, (4) drug, (5) dosage, (6) timing of drug delivery, and (7) total perfusion time. Statistical analysis was performed using nonparametric tests. Results Response rates for ASPSM members ( n  = 45) and non-ASPSM members ( n  = 24) were 89 and 33 %, respectively. Of the responders from ASPSM members, 95 % agreed with implementing the proposal. Majority of the surgical oncologists favored the closed method of delivery with a standardized dual dose of mitomycin for a 90-min chemoperfusion for patients undergoing cytoreductive surgery for peritoneal carcinomatosis of colorectal origin. Conclusions This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field. Studies directed at maximizing the efficacy of each of the seven key elements will need to follow.